Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications

Marcus Hoop, Claudio F. Walde, Raffaele Riccò, Fajer Mushtaq, Anastasia Terzopoulou, Xiang Zhong Chen, Andrew J. deMello, Christian J. Doonan, Paolo Falcaro, Bradley J. Nelson, Josep Puigmartí-Luis, Salvador Pané

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Metal–organic frameworks (MOFs) are a class of crystalline materials constructed from organic linkers and inorganic nodes. MOFs typically possess ultra-high surface areas and pore volumes; thus, they are ideal candidates for biomedical applications. Zinc Imidazolate Framework 8 (ZIF-8) has been widely established in the literature as a potential candidate for on-demand drug delivery applications. Indeed, ZIF-8 has a remarkable loading capacity, stability in physiological environments, and tunable drug release properties. However, the use of ZIF-8 for in vivo applications requires a clear understanding of the interaction of ZIF-8 with biological tissue. In this work, we investigated the biocompatibility of ZIF-8 toward six different cell lines representing various body parts (kidney, skin, breast, blood, bones, and connective tissue). Our results suggest that ZIF-8 has no significant cytotoxicity up to a threshold value of 30 μg mL−1. Above 30 μg mL−1, the cytotoxicity is shown to result from the influence of released Zinc ions (Zn2+) on the mitochondrial ROS production. This adverse effect is responsible for cell cycle arrest in the G2/M phase due to irreversible DNA damage, ultimately initiating cellular apoptosis pathways. Due to this insight, we encapsulated a hormone, insulin, into ZIF-8 particles and then compared its drug delivery capabilities to the aforementioned cytotoxicity values. Our results suggest that ZIF-8 is suitable for therapeutic applications. Furthermore, this study establishes a clear understanding of the interaction of ZIF-8 and its constituents with various cell lines and highlights the important biocompatibility factors that must be considered for future in vivo testing.

Original languageEnglish
Pages (from-to)13-21
Number of pages9
JournalApplied Materials Today
Volume11
DOIs
Publication statusPublished - 1 Jun 2018

Fingerprint

Biocompatibility
Zinc
Metals
Cytotoxicity
Cells
Drug delivery
Tissue
Insulin
Hormones
Cell death
Skin
Bone
DNA
Blood
Ions
Apoptosis
Crystalline materials
Testing

Keywords

  • Biocompatibility
  • Biomedical applications
  • Metal organic framework
  • Zeolitic imidazolate framework
  • ZIF-8
  • Zn

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications. / Hoop, Marcus; Walde, Claudio F.; Riccò, Raffaele; Mushtaq, Fajer; Terzopoulou, Anastasia; Chen, Xiang Zhong; deMello, Andrew J.; Doonan, Christian J.; Falcaro, Paolo; Nelson, Bradley J.; Puigmartí-Luis, Josep; Pané, Salvador.

In: Applied Materials Today, Vol. 11, 01.06.2018, p. 13-21.

Research output: Contribution to journalArticleResearchpeer-review

Hoop, M, Walde, CF, Riccò, R, Mushtaq, F, Terzopoulou, A, Chen, XZ, deMello, AJ, Doonan, CJ, Falcaro, P, Nelson, BJ, Puigmartí-Luis, J & Pané, S 2018, 'Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications' Applied Materials Today, vol. 11, pp. 13-21. https://doi.org/10.1016/j.apmt.2017.12.014
Hoop, Marcus ; Walde, Claudio F. ; Riccò, Raffaele ; Mushtaq, Fajer ; Terzopoulou, Anastasia ; Chen, Xiang Zhong ; deMello, Andrew J. ; Doonan, Christian J. ; Falcaro, Paolo ; Nelson, Bradley J. ; Puigmartí-Luis, Josep ; Pané, Salvador. / Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications. In: Applied Materials Today. 2018 ; Vol. 11. pp. 13-21.
@article{000153569c9343b2a6ba3d05527f20c3,
title = "Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications",
abstract = "Metal–organic frameworks (MOFs) are a class of crystalline materials constructed from organic linkers and inorganic nodes. MOFs typically possess ultra-high surface areas and pore volumes; thus, they are ideal candidates for biomedical applications. Zinc Imidazolate Framework 8 (ZIF-8) has been widely established in the literature as a potential candidate for on-demand drug delivery applications. Indeed, ZIF-8 has a remarkable loading capacity, stability in physiological environments, and tunable drug release properties. However, the use of ZIF-8 for in vivo applications requires a clear understanding of the interaction of ZIF-8 with biological tissue. In this work, we investigated the biocompatibility of ZIF-8 toward six different cell lines representing various body parts (kidney, skin, breast, blood, bones, and connective tissue). Our results suggest that ZIF-8 has no significant cytotoxicity up to a threshold value of 30 μg mL−1. Above 30 μg mL−1, the cytotoxicity is shown to result from the influence of released Zinc ions (Zn2+) on the mitochondrial ROS production. This adverse effect is responsible for cell cycle arrest in the G2/M phase due to irreversible DNA damage, ultimately initiating cellular apoptosis pathways. Due to this insight, we encapsulated a hormone, insulin, into ZIF-8 particles and then compared its drug delivery capabilities to the aforementioned cytotoxicity values. Our results suggest that ZIF-8 is suitable for therapeutic applications. Furthermore, this study establishes a clear understanding of the interaction of ZIF-8 and its constituents with various cell lines and highlights the important biocompatibility factors that must be considered for future in vivo testing.",
keywords = "Biocompatibility, Biomedical applications, Metal organic framework, Zeolitic imidazolate framework, ZIF-8, Zn",
author = "Marcus Hoop and Walde, {Claudio F.} and Raffaele Ricc{\`o} and Fajer Mushtaq and Anastasia Terzopoulou and Chen, {Xiang Zhong} and deMello, {Andrew J.} and Doonan, {Christian J.} and Paolo Falcaro and Nelson, {Bradley J.} and Josep Puigmart{\'i}-Luis and Salvador Pan{\'e}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.apmt.2017.12.014",
language = "English",
volume = "11",
pages = "13--21",
journal = "Applied Materials Today",
issn = "2352-9407",
publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Biocompatibility characteristics of the metal organic framework ZIF-8 for therapeutical applications

AU - Hoop, Marcus

AU - Walde, Claudio F.

AU - Riccò, Raffaele

AU - Mushtaq, Fajer

AU - Terzopoulou, Anastasia

AU - Chen, Xiang Zhong

AU - deMello, Andrew J.

AU - Doonan, Christian J.

AU - Falcaro, Paolo

AU - Nelson, Bradley J.

AU - Puigmartí-Luis, Josep

AU - Pané, Salvador

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Metal–organic frameworks (MOFs) are a class of crystalline materials constructed from organic linkers and inorganic nodes. MOFs typically possess ultra-high surface areas and pore volumes; thus, they are ideal candidates for biomedical applications. Zinc Imidazolate Framework 8 (ZIF-8) has been widely established in the literature as a potential candidate for on-demand drug delivery applications. Indeed, ZIF-8 has a remarkable loading capacity, stability in physiological environments, and tunable drug release properties. However, the use of ZIF-8 for in vivo applications requires a clear understanding of the interaction of ZIF-8 with biological tissue. In this work, we investigated the biocompatibility of ZIF-8 toward six different cell lines representing various body parts (kidney, skin, breast, blood, bones, and connective tissue). Our results suggest that ZIF-8 has no significant cytotoxicity up to a threshold value of 30 μg mL−1. Above 30 μg mL−1, the cytotoxicity is shown to result from the influence of released Zinc ions (Zn2+) on the mitochondrial ROS production. This adverse effect is responsible for cell cycle arrest in the G2/M phase due to irreversible DNA damage, ultimately initiating cellular apoptosis pathways. Due to this insight, we encapsulated a hormone, insulin, into ZIF-8 particles and then compared its drug delivery capabilities to the aforementioned cytotoxicity values. Our results suggest that ZIF-8 is suitable for therapeutic applications. Furthermore, this study establishes a clear understanding of the interaction of ZIF-8 and its constituents with various cell lines and highlights the important biocompatibility factors that must be considered for future in vivo testing.

AB - Metal–organic frameworks (MOFs) are a class of crystalline materials constructed from organic linkers and inorganic nodes. MOFs typically possess ultra-high surface areas and pore volumes; thus, they are ideal candidates for biomedical applications. Zinc Imidazolate Framework 8 (ZIF-8) has been widely established in the literature as a potential candidate for on-demand drug delivery applications. Indeed, ZIF-8 has a remarkable loading capacity, stability in physiological environments, and tunable drug release properties. However, the use of ZIF-8 for in vivo applications requires a clear understanding of the interaction of ZIF-8 with biological tissue. In this work, we investigated the biocompatibility of ZIF-8 toward six different cell lines representing various body parts (kidney, skin, breast, blood, bones, and connective tissue). Our results suggest that ZIF-8 has no significant cytotoxicity up to a threshold value of 30 μg mL−1. Above 30 μg mL−1, the cytotoxicity is shown to result from the influence of released Zinc ions (Zn2+) on the mitochondrial ROS production. This adverse effect is responsible for cell cycle arrest in the G2/M phase due to irreversible DNA damage, ultimately initiating cellular apoptosis pathways. Due to this insight, we encapsulated a hormone, insulin, into ZIF-8 particles and then compared its drug delivery capabilities to the aforementioned cytotoxicity values. Our results suggest that ZIF-8 is suitable for therapeutic applications. Furthermore, this study establishes a clear understanding of the interaction of ZIF-8 and its constituents with various cell lines and highlights the important biocompatibility factors that must be considered for future in vivo testing.

KW - Biocompatibility

KW - Biomedical applications

KW - Metal organic framework

KW - Zeolitic imidazolate framework

KW - ZIF-8

KW - Zn

UR - http://www.scopus.com/inward/record.url?scp=85041567199&partnerID=8YFLogxK

U2 - 10.1016/j.apmt.2017.12.014

DO - 10.1016/j.apmt.2017.12.014

M3 - Article

VL - 11

SP - 13

EP - 21

JO - Applied Materials Today

JF - Applied Materials Today

SN - 2352-9407

ER -